MYELOPROLIFERATIVE NEOPLASM

This early-phase trial tests whether specially trained natural killer (NK) cells can safely prevent blood cancers like leukemia from coming back after a stem cell transplant. About 15 adults with high-risk disease will receive an infusion of these cells plus a supportive drug. Th…

This study tests a combination of two or three drugs (ivosidenib, venetoclax, with or without azacitidine) in people with certain blood cancers that have an IDH1 mutation. The goal is to find the best dose and see how well the drugs control the cancer. About 96 adults with acute …

This study tests two different methods to lower the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body, after a stem cell transplant. The trial includes 120 adults with acute leukemia or myelodysplastic syndrome (MDS) whos…

This study tests a two-step approach for people with advanced myeloproliferative neoplasms (blood cancers). First, patients receive a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) to reduce cancer cells. Then, they undergo a donor…

This study tests a new way to prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers who receive a donor stem cell transplant. Researchers remove a specific type of immune cell (naive T cells) from the donor cells before transplant to red…

This study tests whether a drug called dexrazoxane can protect the heart from damage caused by chemotherapy in people with certain blood cancers, like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). About 100 participants will receive dexrazoxane alongs…

This early-phase study tests a new type of immune cell (CIML NK cells) combined with a low-dose drug (IL-2) in people whose leukemia or related blood cancers have returned after a stem cell transplant. The goal is to find a safe dose and see if it can put the cancer back into rem…

This study tests whether combining two drugs—CPX-351 (a chemotherapy) and ivosidenib (a targeted therapy)—can better control acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that have an IDH1 gene mutation. About 30 adults who are either newly diagnosed or…

This study tests a refined cord blood transplant method for people with high-risk blood cancers like leukemia and lymphoma. Participants receive chemotherapy and radiation before the transplant to prepare the body, then drugs after to prevent rejection. The goal is to improve sur…

This study tests whether combining two drugs, venetoclax and azacitidine, is safe and effective for people whose myeloproliferative neoplasm (MPN) has advanced to a more aggressive phase. About 40 participants will receive the combination therapy. The goal is to see if the treatm…

This early-stage trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV), a common and dangerous infection after transplant. About 46 people with various blood cancers or disorders will take part. The g…

This study tests a vaccine (CMV-MVA Triplex) given to stem cell donors to help prevent CMV infection in patients receiving a stem cell transplant. The vaccine boosts the donor's immunity against CMV, which is then passed to the patient through the transplant. About 216 donor-reci…

This study looks at whether N-Acetylcysteine (N-AC), a common supplement, can reduce symptoms like fatigue and pain in adults with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. About 27 participants with essential thrombocythemia, polycythemia vera, or myelo…

This early-phase study tests whether two metal-removing drugs (edetate calcium disodium and succimer) are safe and can help control acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) when given alongside chemotherapy. About 58 adults with these blood cancers will rece…

This study is a large registry for children and young adults with cancer. It collects health information and leftover tumor or blood samples over time. The goal is to help doctors find better ways to treat and care for these patients. Up to 75,000 people will take part.

This study is looking for better ways to predict blood clots in people with myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will measure specific markers in the blood of 300 participants to see if these markers can identify who is at higher risk for clo…

This study looks at whether measuring changes in a gene called CALR can help doctors predict when a type of blood cancer (myeloproliferative neoplasm) gets worse. Researchers will follow 260 adults diagnosed between 2006 and 2020, using stored blood samples and medical records. N…

This study is testing whether an artificial intelligence (AI) tool can help match people with advanced cancer to the right clinical trials. Researchers will enroll up to 50,000 participants to see if the AI improves trial enrollment rates and patient outcomes. The goal is to make…

This study looks at a type of immune cell called monocytes in people with certain blood cancers (myeloproliferative neoplasms). Researchers want to see if these cells have unique features that could help diagnose the disease more accurately. About 70 adults with polycythemia vera…

This study looks at why people with a CALR gene mutation and a type of blood cancer called myeloproliferative neoplasm (MPN) have a lower risk of dangerous blood clots compared to those with a different mutation (JAK2). Researchers will collect blood samples from 35 adults with C…

This study aims to find out why some people with certain blood cancers (polycythemia vera, essential thrombocythemia, and pre-myelofibrosis) respond well to standard treatments while others do not. Researchers will analyze genetic and immune factors in 120 adults starting treatme…

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured. T…

This study looks at how services from a non-profit cancer advocacy organization affect people with blood cancers like leukemia and lymphoma. Researchers will track 400 patients over time to see if the group's programs improve access to care, quality of life, and reduce financial …

This study aims to understand exactly how the drug interferon attacks cancer cells in people with certain blood cancers called myeloproliferative neoplasms (MPNs). Researchers will analyze blood samples from 80 adults to see why some patients respond well and others do not. The g…